Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016 (2016), Article ID 3743427, 6 pages
http://dx.doi.org/10.1155/2016/3743427
Research Article

The Score Model Containing Chinese Medicine Syndrome Element of Blood Stasis Presented a Better Performance Compared to APRI and FIB-4 in Diagnosing Advanced Fibrosis in Patients with Chronic Hepatitis B

Hepatology Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, China

Received 5 October 2015; Revised 27 December 2015; Accepted 28 December 2015

Academic Editor: Makoto Arai

Copyright © 2016 Xiao-Ling Chi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M.-F. Yuen, H.-J. Yuan, D. K.-H. Wong et al., “Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications,” Gut, vol. 54, no. 11, pp. 1610–1614, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Alam, N. Ahmad, G. Mustafa, A. Shrestha, A. K. M. K. Alam, and M. Khan, “Evaluation of normal or minimally elevated alanine transaminase, age and DNA level in predicting liver histological changes in chronic hepatitis B,” Liver International, vol. 31, no. 6, pp. 824–830, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. B. L. Liao, Z. H. Wang, S. W. Lin et al., “Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT,” PLoS ONE, vol. 8, no. 10, Article ID e78672, 2013. View at Publisher · View at Google Scholar
  4. L.-H. Zhong, Y.-M. Jiang, G.-Q. Lou et al., “The relationship between serum HBsAg levels and liver inflammation and fibrosis in patients with chronic hepatitis B,” Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, vol. 27, no. 2, pp. 92–94, 2013. View at Google Scholar · View at Scopus
  5. Y.-H. Huang, Z.-J. Yu, C. Wang, B. Zhou, and J.-L. Hou, “Relationship between hepatitis B virus genotypes and liver fibrosis,” Nan Fang Yi Ke Da Xue Xue Bao, vol. 27, no. 7, pp. 1012–1014, 2007. View at Google Scholar · View at Scopus
  6. Y. Wang, M.-Y. Xu, R.-D. Zheng et al., “Prediction of significant fibrosis and cirrhosis in hepatitis B e-antigen negative patients with chronic hepatitis B using routine parameters,” Hepatology Research, vol. 43, no. 5, pp. 441–451, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. Chinese Society of Hepatology and Chinese Society of Infectious Diseases. Chinese Medical Association, “The guideline of prevention and treatment for chronic hepatitis B (2010 version),” Zhonghua Liu Xing Bing Xue Za Zhi, vol. 32, no. 4, pp. 405–415, 2011. View at Google Scholar
  8. Liver Disease Committee. Chinese Association of Integrative Medicine, “Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice,” Chinese Journal of Hepatology, vol. 14, no. 11, pp. 866–870, 2006. View at Google Scholar
  9. Professional Committee of Liver Diseases of China Association of Chinese Medicine, “Standards of traditional Chinese medicine syndrome differentiation for viral hepatitis (trial implementation,” Zhong Yi Za Zhi, no. 5, pp. 39–40, 1992. View at Google Scholar
  10. Liver Disease Committee and World Federation of Chinese Medicine Societies, “The diagnostic standard of Traditional Chinese Medicine syndrome elements for Chronic Hepatitis B patients,” Journal of Chinese Medicine, vol. 55, no. 11, 2014. View at Google Scholar
  11. M.-D. Zeng, L.-G. Lu, Y.-M. Mao et al., “Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model,” Hepatology, vol. 42, no. 6, pp. 1437–1445, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. X.-Y. Xu, H. Kong, R.-X. Song et al., “The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy,” PLoS ONE, vol. 9, no. 6, Article ID e100182, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. X. Hu, Z. Liu, and J. Sun, “Explanation of the ‘guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection 2015’: non-invasive assessment of liver fibrosis, treatment strategy and implementation of national programs,” Journal of Clinical Hepatology, vol. 31, no. 6, pp. 829–832, 2015. View at Google Scholar
  14. H.-P. Xie, H.-Z. Yang, W.-K. Wu et al., “Chinese medicine syndrome distribution of chronic hepatitis B virus carriers in immunotolerant phase,” Chinese Journal of Integrative Medicine, vol. 20, no. 2, pp. 94–100, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. M. Tang, Q. J. Ru, and Z. E. Zhang, “Clinical study on relationship between liver-blood stasis and liver fibrosis,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 17, no. 2, pp. 81–83, 1997. View at Google Scholar · View at Scopus
  16. S. Y. Liu, Y. Q. Zhang, Y. L. Liu, P. Guo, and C. M. Zhou, “Intervention of chronic hepatitis B liver fibrosis patients in different stages by syndrome typing and different activating blood removing stasis methods: a clinical study,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 33, no. 11, pp. 1457–1461, 2013. View at Google Scholar